Antibiotic interaction study for prostate cancer drug completed

NCT ID NCT07014488

Completed Knowledge-focused Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study tested how the antibiotic rifampicin changes the way the body processes HRS-5041, an experimental drug for prostate cancer. Sixteen healthy men took HRS-5041 with and without rifampicin to measure drug levels and safety. The goal was to understand potential drug interactions before testing HRS-5041 in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-5041 tablets and rifampicin capsules
What this could lead to: If successful, this study could help determine the right dose of HRS-5041 when taken with rifampicin, potentially improving future prostate cancer treatment.
What could go wrong: This is a very early, small study in healthy people, not patients. It only looks at drug levels, not whether HRS-5041 works for prostate cancer. Results may not apply to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Jinan, Shandong, 250014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.